Li et al. [107] found that lncRNA OR3A4 drove angiogenesis in HCC by modulating the AGGF1/AKT/mTOR pathway, which identifies OR3A4 as a promising therapeutic target for HCC. Here, MTOR is linked to hepatocellular carcinoma.